Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy.

Hines, Philip A; Gonzalez-Quevedo, Rosa; Lambert, Apolline I O M; Janssens, Rosanne; Freischem, Barbara; Torren Edo, Jordi; Claassen, Ivo J T M; Humphreys, Anthony J

Hines, Philip A; Gonzalez-Quevedo, Rosa; Lambert, Apolline I O M; Janssens, Rosanne; Freischem, Barbara; Torren Edo, Jordi; Claassen, Ivo J T M; Humphreys, Anthony J.

Afiliação

Hines PA; European Medicines Agency, Amsterdam, Netherlands.
Gonzalez-Quevedo R; United Nations University-Maastricht Economic and Social Research Institute on Innovation & Technology (UNU-MERIT), Maastricht University, Maastricht, Netherlands.
Lambert AIOM; European Medicines Agency, Amsterdam, Netherlands.
Janssens R; European Medicines Agency, Amsterdam, Netherlands.
Freischem B; European Medicines Agency, Amsterdam, Netherlands.
Torren Edo J; Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Claassen IJTM; European Medicines Agency, Amsterdam, Netherlands.
Humphreys AJ; European Medicines Agency, Amsterdam, Netherlands.

Front Med (Lausanne) ; 7: 508, 2020.

Article em En | MEDLINE | ID: mdl-33072771

Palavras-chave

benefit-risk assessment; innovation; patient access; regulation; regulatory science; stakeholder engagement

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google